Effect of nebivolol and metoprolol treatments on serum asymmetric dimethylarginine levels in hypertensive patients with type 2 diabetes mellitus

Anadolu Kardiyoloji Dergisi

Volumn 7, Issue 4, 2007, Pages 383-387

  Oǧuz, Aytekin ^a   Uzunlulu, Mehmet ^a,d   Yorulmaz, Elif ^a   Yalçin, Yavuz ^a   Hekim, Nezih ^b   Fici, Francesco ^c  

^a GOZTEPE TRAINING AND RESEARCH HOSPITAL   (Turkey)

^b Dr Pakize i Tarzi Laboratuarlari Turkey   (Turkey)

^c SECOND UNIVERSITY OF NAPLES   (Italy)

^d Altay esme Mahallesi   (Turkey)

Author keywords

Asymmetric dimethylarginine; Diabetes; Endothelial dysfunction; Hypertension; Metoprolol; Nebivolol

Indexed keywords

INDAPAMIDE; METOPROLOL; N(G),N(G) DIMETHYLARGININE; NEBIVOLOL; ORAL ANTIDIABETIC AGENT;

ADULT; AGED; AMINO ACID BLOOD LEVEL; ANTIHYPERTENSIVE THERAPY; ARTICLE; BLOOD PRESSURE REGULATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; ENDOTHELIUM LESION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; OPEN STUDY; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; STATISTICAL SIGNIFICANCE; UNSPECIFIED SIDE EFFECT;

ADMINISTRATION, ORAL; ADRENERGIC BETA-ANTAGONISTS; ADULT; AGED; ARGININE; BENZOPYRANS; BIOLOGICAL MARKERS; BLOOD PRESSURE; CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; ETHANOLAMINES; FEMALE; HUMANS; HYPERTENSION; MALE; METOPROLOL; MIDDLE AGED; PROSPECTIVE STUDIES; TREATMENT OUTCOME; TRIGLYCERIDES;

EID: 37349101931     PISSN: 13028723     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (50)

1. Hobbs FD. Type-2 diabetes mellitus related cardiovascular risk: New options for interventions to reduce risk and treatments goals. Atheroscler Suppl 2006; 7: 29-32.
2. De Vriese AS, Verbeuren T J, Van de Voorde J, Lameire NH, Vanhoutte PM. Endothelial dysfunction in diabetes. Br J Pharmacol 2000; 130: 963-74.
3. Zoghi M, Nalbantgil I. Hypertension and endothelial dysfunction. Anadolu Kardiyol Derg 2002; 2: 142-7.
4. Cooke JP, Dzau VJ. Derangements of the nitric oxide synthase pathway, L-arginine, and cardiovascular diseases. Circulation 1997; 90: 379-82.
5. Vallance P, Chan NN. Endothelial function and nitric oxide: clinical relevance. Heart 2001; 85: 342-50.
6. Dandona P, Chaudhuri A, Aljada A. Endothelial dysfunction and hypertension in diabetes mellitus. Med Clin North Am 2004; 88: 911-31.
7. Vallance P, Leone AM, Calver A, Collier J, Moncada S. Endogenous dimethylarginine as an inhibitor of nitric oxide synthase. J Cardiovasc Pharmacol 1992; 20 (Suppl 12): S60-2.
8. Stühlinger MC, Abbasi F, Chu JW, Lamendola C, McLaughlin TL, Cooke JP, et al. Relationship between insulin resistance and an endogenous nitric oxide synthase inhibitor. JAMA 2002; 287: 1420-6.
9. Cooke JP. Does ADMA cause endothelial dysfunction? Arterioscler Thromb Vasc Biol. 2000; 20: 2032-7.
10. Abbasi F, Asagmi T, Cooke JP, Lamendola C. Plasma concentrations of asymmetric dimethylarginine are increased in patients with type 2 diabetes mellitus. Am J Cardiol 200; 88: 1201-3.
11. Takiuchi S, Fujii H, Kamide K, Horio T, Nakatani S, Hiuge A, et al. Plasma asymmetric dimethylarginine and coronary and peripheral endothelial dysfunction in hypertensive patients. Am J Hypertens 2004; 17: 802-8.
12. Zanchetii A. Clinical pharmacodynamics of nebivolol: new evidence of nitric oxide-mediated vazodilating activity and peculiar haemodynamic properties in hypertensive patients. Blood Press Supp1 2004; 1: 17-32.
13. Demiralp E, Kardesoglu E, Celik T, Cebeci BS, Ozmen N, Isilak Z, et al. Short-term effect of nebivolol on the left ventricular diastolic function. Anadolu Kardiyol Derg 2004; 4: 323-36.
14. Weber MA. The role of the new beta-blockers in treating cardiovascular disease. Am J Hypertens 2005; 18: S169-76.
15. Arauz-Pachero C, Parrott MA, Raskin P. The treatment of hypertension in adult patients with diabetes. Diabetes Care 2002; 25: 134-47.
16. The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus: Report of The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 1997; 20 (Suppl1): 1183-97.
17. Maggio CA, Pi-Sunyer FX. The prevention and treatment of obesity: application to type 2 diabetes. Diabetes Care 1997; 20: 1744-66.
18. Haffner SM, Kennedy E, Gonzalez C, Stern MP, Miettinen H. A prospective analysis of the HOMA model: the Mexico City Diabetes Study. Diabetes Care 1996; 19: 1138-41.
19. Beltowski J, Kedra A. Asymmetric dimethylarginine (ADMA) as a target for pharmacotherapy. Pharmacol Rep 2006; 58: 159-78.
20. Lu TM, Ding YA, Lin S J, Lee WS, Tai HC. Plasma levels of asymmetrical dimethylarginine and adverse cardiovascular events after percutaneous coronary intervention. Eur Heart J 2003; 24: 1912-9.
21. Boger RH. Asymmetric dimethylarginine (ADMA): a novel risk marker in cardiovascular medicine and beyond. Ann Med 2006; 38: 126-36.
22. Zoccali C. Asymmetric dimethylarginine (ADMA): a cardiovascular and renal risk factor on the move. J Hypertens 2006; 24: 611-9.
23. Lin KY, Ito A, Asagami T, Tsao PS, Adimoolam S, Kimoto M, et al. Impaired nitric oxide synthase pathway in diabetes mellitus: role of asymmetric dimethylarginine and dimethylarginine dimethylaminohydrolase. Circulation 2002; 20: 987-92.
24. Perticone F, Sciacqua A, Maio R, Perticone M, Maas R, Beger RH, et al. Asymmetric dimethylarginine, L-arginine, and endothelial dysfunction in essential hypertension. J Am Coll Cardiol 2005; 46: 518-23.
25. Surdacki A, Nowicki M, Sandmann J, Tsikas D, Boeger RH, Bode-Boeger SM, et al. Reduced urinary excretion of nitric oxide metabolites and increased plasma levels of asymmetric dimethylarginine in men with essential hypertension. J Cardiovasc Pharmacol 1999; 33: 652-8.
26. Leiper J, Vallance P. Biological significance of endogenous methylarginines that inhibit nitric oxide synthases. Cardiovasc Res 1999; 43: 542-8.
27. Napoli C, Sica V, de Nigris F, Pignalosa O, Condorelli M, Ignarro L J, et al. Sulphydryl angiotensin-converting enzyme inhibition induces sustained reduction of systemic oxidative stress and improves the nitric oxide pathway in patients with essential hypertension Am Heart J 2004; 148: e5.
28. Redon J, Oliva MR, Termos C, Giner V, Chaves J, Iradi A, et al. Antioxidant activities and oxidative stress byproducts in human hypertension. Hypertension 2003; 41: 1096-101.
29. Sydow K, Munzel T. ADMA and exidative stress. Atheroscler Suppl 2003; 4: 41-51.
30. Stuhlinger MC, Tsao PS, Kimoto M, Cooke JP. Homocysteine induced accumulation of asymmetric dimethylarginine: role of DDAH and effect of antioxidants. Circulation 2000; 102 (Suppl): A1-177.
31. MacAllister RJ, Fickling SA, Whitley GS, Vallance P. Metabolism of methylarginines by human vasculature: implication for the regulation of nitric oxide synthesis. Br J Pharmacol 1994; 112: 43-8.
32. Chen JW, Hsu NW, Wu TC, Lin SJ, Chang MS. Long-term angiotensin-converting enzyme inhibition reduces plasma asymmetric dimethylarginine and improves endothelial nitric oxida bioavailability and coronary microvascular function in patients with syndrome X. Am J Cardiol 2002; 90: 974-82.
33. Delles C, Schneider MP, John S, Gekle M, Schmieder E. Angiotensin converting enzyme inhibition and angiotensin II AT1-receptor bleckade reduce the levels of asymmetrical N (G), N(G)-dimethylarginine in human essential hypertension. Am J Hypertens 2002; 15: 590-3.
34. Ite A, Egashira K, Narishige T, Muramatsu K, Takeshita A. Angiotensin-converting enzyme activity is involved in the mechanism of increased endogenous nitric oxide synthase inhibitor in patients with type 2 diabetes mellitus. Circ J 2002; 66: 811-5.
35. Hollenberg NK. The role of beta-blockers as a cornerstone of cardiovascular therapy. Am J Hypertens 2005; 18: 165-8.
36. Mason RP, Kubant R, Jacob RF, Walter MF, Boychuk B, Malinski T. Effect of nebivolol on endothelial nitric oxide and peroxynitrite release in hypertensive animals: role of antioxidant activity. J Cardiovasc Pharmacol 2006; 48: 862-9.
37. Ladage D, Brixius K, Hoyer H, Steingen C, Wesseling A, Malan D, et al. Mechanisms underlying nebivolol-induced endothelial nitric oxide synthase activation in human umbilical vein endothelial cell. Clin Exp Pharmacol Physiol 2006; 33: 720-4.
38. Dawes M, Brett SE, Chowienczyk P J, Mant TG, Ritter JM. The vasodilator action of nebivolol in forearm vasculature of subjects with essential hypertension. Br J Clin Pharmacol 1999; 48: 460-3.
39. Cockcroft JR, Chowienczyk PJ, Brett SE, Chen CP, Dupont AG, Van Nueten L, et al. Nebivolol vasodilates human forearm vasculature: Evidance for an l-arginine/NO- dependent mechanism. J Pharmacol Exp Therap 1995; 374: 1067-71.
40. Tzemos N, Lim PO, MacDonald TM. Nebivolol reverses endothelial dysfunction in essential hypertension: a randomized, double-blind, cross-over study. Circulation 2001; 104: 511-4.
41. Lekakis JP, Protogeron A, Papamichael C, Vamvakou G, Iconomidis I, Fici F, et al. Effect of nebivolol and atenolol on brachial artery flow-mediated vasodilation in patients with coronary artery disease. Cardiovasc Drugs Ther 2005; 19: 277-81.
42. Dessy C, Saliez J, Ghisdel P, Daneau G, Lobysheve II, Frerart F, et al. Endotheliel beta-3 adrenoreceptors mediate nitric oxide-dependent vasorelaxation of coronary microvessels in response to the third-generation beta-blocker nebivolol. Circulation 2005; 112: 1198-205.
43. Fratta Pasini A, Garbin U, Nava MC, Stranieri C, Davoli A, Sawamura T, et al. Nebivolol decreases oxidative stress in essential hypertensive patients and increases nitric oxide by reducing its oxidative inactivation. J Hypertens 2005; 23: 589-96.
44. Baykal Y, Yilmaz MI, Celik T, Gok F, Rehber H, Akay C, et al. Effects of entihypertensive agents, alpha receptor blockers, beta blockers, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers and calcium channel blockers, on oxidative stress. J Hypertens 2003; 21: 1207-11.
45. Lenzen H, Tsikas D, Boger RH. Asymmetric dimethylarginine (ADMA) and the risk for coronary heart disease: the multicenter CARDIAC study. Eur J Clin Pharmacol 2006; 62 Suppl 13: 45-9.
46. Post MS, Verhoeven MO, van der Mooren M J, Kenemans P, Stehouwer CD, Teerlink T. Effect of hormone replacement tharapy on plasma levels of the cardiovascular risk factor asymmetric dimethylarginine: a randomized, placebo-controlled 12-week study in healthy early postmenopausal women. J Clin Endocrinol Metab 2003; 88: 4221-6.
47. Maas R. Pharmacotherapies and their influence on asymmetric dimethylarginine (ADMA). Vasc Med 2005; 10 Suppl 1: S49-57.
48. Asagami T, Abbasi F, Stuelinger M, Lamendola C, McLaughlin T, Cooke JP, et al. Metformin treatment lowers asymmetric dimethylarginine concentrations in patients with type 2 diabetes. Metabolism 2002; 51:848-6.
49. Yang TL, Chen MF, Xia X, Luo BL, Li YJ. Effect of fenofibrate on the level of asymmetric dimethylarginine in individuals with hypertriglyceridemia. Eur J Clin Pharmacol 2008; 62: 179-84.
50. Lundman P, Eriksson MJ, Stuhlinger M, Cooke JP, Hamsten A, Tornvall P. Mild-to-moderate hypertriglyceridemia in young men is associated with endothelial dysfunction and increased plasma concentrations of asymmetric dimethylarginine. J Am Coll Cardiol 2001; 38: 111-6.